Recent News

• 06.04.2025 - 2025 Jefferies Global Healthcare Conference
• 06.04.2025 - 2025 Jefferies Global Healthcare Conference
• 06.04.2025 - Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
• 06.04.2025 - Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
• 05.28.2025 - Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
• 05.28.2025 - Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
• 05.20.2025 - 2025 RBC Capital Markets Healthcare Conference
• 05.20.2025 - 2025 RBC Capital Markets Healthcare Conference
• 05.13.2025 - Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
• 05.13.2025 - Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

Recent Filings

• 05.23.2025 - 3 Initial statement of beneficial ownership of securities
• 05.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - EFFECT Notice of Effectiveness
• 05.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.07.2025 - S-3 Registration statement under Securities Act of 1933
• 05.07.2025 - EX-99.1 EX-99.1
• 05.07.2025 - 8-K Current report